Files

Abstract

The present disclosure provides combinations of immunologic inhibitors for the treatment of cancer. In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7.

Details

Actions

PDF

from
to
Export
Download Full History